Institution Directory

Clinical trials at University of Alabama at Birmingham

Sites in Birmingham, AL

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 12:24 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1235

Shown on this page

Current sort

Live official records

Conditions: Acute Respiratory Distress Syndrome (ARDS), ARDS, ARDS (Acute Respiratory Distress Syndrome), Acute Respiratory Distress Syndrome
Interventions: Cohort A: vilobelimab, Cohort A: placebo; Drug
Lead sponsor: PPD Development, LP; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 41
States / cities: Birmingham, Alabama • Fresno, California • Long Beach, California + 34 more

Conditions: Hematological Malignancies
Interventions: Teclistamab; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 194 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 10
States / cities: Birmingham, Alabama • Duarte, California • San Francisco, California + 6 more

Conditions: Cervical Carcinoma, Human Papillomavirus Infection
Interventions: Biospecimen Collection, Cervical Biopsy, Colposcopy, Electronic Health Record Review, Endocervical Curettage, Excision, HPV Self-Collection, Human Papillomavirus Test, Questionnaire Administration; Procedure · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 25 Years and older · Female only
Enrollment: 500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 18
States / cities: Birmingham, Alabama • Atlanta, Georgia • Lafayette, Louisiana + 12 more

Conditions: Acute Respiratory Distress Syndrome (ARDS), ARDS, ARDS (Acute Respiratory Distress Syndrome), Acute Respiratory Distress Syndrome
Interventions: Cohort A: vilobelimab, Cohort A: placebo, Cohort B: paridiprubart, Cohort B: placebo, Cohort C: bevacizumab, Cohort C: placebo; Drug
Lead sponsor: PPD Development, LP; Industry
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 41
States / cities: Birmingham, Alabama • Fresno, California • Long Beach, California + 34 more

Conditions: Acute Respiratory Distress Syndrome (ARDS), ARDS, ARDS (Acute Respiratory Distress Syndrome), Acute Respiratory Distress Syndrome
Interventions: Cohort B: paridiprubart, Cohort B: placebo; Drug
Lead sponsor: PPD Development, LP; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 41
States / cities: Birmingham, Alabama • Fresno, California • Long Beach, California + 34 more

Conditions: Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Ureter Urothelial Carcinoma, Locally Advanced Urethral Urothelial Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis Urothelial Carcinoma, Metastatic Ureter Urothelial Carcinoma, Metastatic Urethral Urothelial Carcinoma, Recurrent Bladder Urothelial Carcinoma, Recurrent Renal Pelvis Urothelial Carcinoma, Recurrent Ureter Urothelial Carcinoma, Recurrent Urethral Urothelial Carcinoma, Stage III Bladder Cancer AJCC v8, Stage III Renal Pelvis Cancer AJCC v8, Stage III Ureter Cancer AJCC v8, Stage III Urethral Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8, Stage IV Renal Pelvis Cancer AJCC v8, Stage IV Ureter Cancer AJCC v8, Stage IV Urethral Cancer AJCC v8, Unresectable Bladder Urothelial Carcinoma, Unresectable Renal Pelvis Urothelial Carcinoma, Unresectable Ureter Urothelial Carcinoma, Unresectable Urethral Urothelial Carcinoma
Interventions: Atezolizumab, Biopsy Procedure, Biospecimen Collection, Computed Tomography with Contrast, Eribulin Mesylate; Drug · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 21
States / cities: Birmingham, Alabama • Buena Park, California • Duarte, California + 15 more

Conditions: Acute Respiratory Distress Syndrome (ARDS), ARDS, ARDS (Acute Respiratory Distress Syndrome), Acute Respiratory Distress Syndrome
Interventions: Cohort C: bevacizumab, Cohort C: placebo; Drug
Lead sponsor: PPD Development, LP; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 41
States / cities: Birmingham, Alabama • Fresno, California • Long Beach, California + 34 more

Conditions: Wounds, Wounds and Injuries, Extremity Injury, Traumatic Wounds and Injuries, Amputation, Traumatic/Surgery, Amputation, Wound, Open Fracture Wounds
Interventions: Clinical Decision Support Tool, Standard of Care (SOC); Device · Procedure
Lead sponsor: Henry M. Jackson Foundation for the Advancement of Military Medicine; Other
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 5
States / cities: Birmingham, Alabama • Atlanta, Georgia • Indianapolis, Indiana + 2 more

Conditions: Brain Metastases
Interventions: brain metastases radiosurgery; Procedure
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, HIV (Human Immunodeficiency Virus)
Interventions: Resmetirom, Placebo Control; Drug
Lead sponsor: Naga P. Chalasani; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 10
States / cities: Birmingham, Alabama • La Jolla, California • San Francisco, California + 7 more

Conditions: Osteosarcoma, Osteosarcoma in Children, Osteosarcoma Recurrent, Sarcoma
Interventions: Nivolumab, Azacitidine, Post Treatment Surgery; Drug · Procedure
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: Up to 39 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 22
States / cities: Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 19 more

Conditions: Endometrial Cancer, Endometrial Cancer Precursors, Ovarian Cancer, Complex Atypical Endometrial Hyperplasia
Interventions: Not listed
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 99 Years · Female only
Enrollment: 1,700 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Birmingham, Alabama

About this University of Alabama at Birmingham institution page

What this page lists: ClinicalTrials.gov records that list University of Alabama at Birmingham in Birmingham, AL as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at University of Alabama at Birmingham

Filter and sort this campus

Live official records

JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort A: Vilobelimab

A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S04)

JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS (Master Record)

JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort B: Paridiprubart

Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer

JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort C: Bevacizumab

Pilot Trial for WounDx™ Clinical Decision Support Tool

Trial of Differential Margins in Single Isocenter Radiosurgery of Brain Metastases

A Study to Evaluate the Use of Resmetirom in Participants With MASLD and HIV

Nivolumab or Nivolumab and Azacitidine in Patients With Recurrent, Resectable Osteosarcoma

The DETECT Study: Discovery and Evaluation of Testing for Endometrial and Ovarian Cancer in Tampons

About this University of Alabama at Birmingham institution page